Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Federal University of São Paulo

Status

Completed

Conditions

Breast Cancer

Treatments

Drug: Anastrozole

Study type

Interventional

Funder types

Other

Identifiers

NCT01016665

0904/04

Details and patient eligibility

About

Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment.

Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT).

Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.

Enrollment

71 patients

Sex

Female

Ages

40 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Invasive breast cancer post-menopausal women
Estrogen and/or progesterone receptor positive

Exclusion criteria

Patients with endocrine disease
Hormone therapy users or those who had been pregnant in the last 12 months before the diagnosis
Patients with a negative expression for estrogen and/or progesterone receptors
Women with a history of thromboembolism
Patients who had previously undergone any treatment for breast cancer